{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42","upperLimit":"78","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"The 2-year PFS was measured from the date of enrollment to the first occurrence of new metastatic lesions, objective tumor progression, or death. The combination of cisplatin and cetuximab concurrent with radiation therapy for head and neck cancer has shown to have a favorable PFS. Patients were followed until death or from 7.5 months to 63.6 months (median 25.6 months) in those alive at last evaluation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nab-Paclitaxel, Cetuximab, Cisplatin, and Intensity-modulated radiation therapy (IMRT)","id":"OG000","title":"Single Arm: Chemotherapy With Concurrent Radiation Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 year from the date of enrollment","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}